Uso de vericiguat en pacientes con falla cardiaca y fracción de eyección reducida
DOI:
https://doi.org/10.36314/cunori.v7i2.233Keywords:
vericiguat, pharmacological, mortality, reduced, cardiovascularAbstract
PROBLEM: the population with heart failure represents a high rate of hospital admissions, mortality and cardiovascular events in all developed and underdeveloped countries. The therapy of these has evolved a lot in the last decades, but despite this, patients who suffer multiple events secondary to this pathology are always appreciated. The new pharmacological treatments represent a feasible alternative for those patients who present worsening despite having a target treatment, dictated by the latest heart failure treatment guidelines. OBJECTIVE: to describe the use of vericiguat in patients with heart failure and reduced ejection fraction. MATERIAL AND METHODS: for the development of the study, a bibliographic review was carried out, based on primary sources, in which scientific articles and meta-analyses were taken into account. CONCLUSION: Among the main beneficial effects of vericiguat, it was evidenced that the primary events of cardiovascular death and first hospitalization were lower in patients with heart failure with reduced ejection fraction; which also proved to be safe in patients regardless of their initial renal function, not showing complications or deterioration of the same during its use and it also proved to maintain its effectiveness in patients with atrial fibrillation.
Downloads
References
Butler, J., Stebbins, A., Melenovský, V., Sweitzer, N. K., Cowie, M. R., Stehlik, J., Khan, M. S., Blaustein, R. O., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., Nkulikiyinka, R., O’Connor, C. M., Pieske, B. M., Ponikowski, P., Spertus, J. A., Voors, A. A., Anstrom, K. J., & Armstrong, P. W. (2022). Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation. Heart Failure, 15(6), E009337. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337
Follmann, M., Ackerstaff, J., Redlich, G., Wunder, F., Lang, D., Kern, A., Fey, P., Griebenow, N., Kroh, W., Becker-Pelster, E. M., Kretschmer, A., Geiss, V., Li, V., Straub, A., Mittendorf, J., Jautelat, R., Schirok, H., Schlemmer, K. H., Lustig, K., … Stasch, J. P. (2017). Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. Journal of Medicinal Chemistry, 60(12), 5146–5161. https://doi.org/10.1021/ACS.JMEDCHEM.7B00449/SUPPL_FILE/JM7B00449_SI_002.CSV DOI: https://doi.org/10.1021/acs.jmedchem.7b00449
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., Samano, E. T., Muller, K., Roessig, L., & Pieske, B. (2015). Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA, 314(21), 2251–2262. https://doi.org/10.1001/JAMA.2015.15734 DOI: https://doi.org/10.1001/jama.2015.15734
Gheorghiade, M., Marti, C. N., Sabbah, H. N., Roessig, L., Greene, S. J., Böhm, M., Burnett, J. C., Campia, U., Cleland, J. G. F., Collins, S. P., Fonarow, G. C., Levy, P. D., Metra, M., Pitt, B., Ponikowski, P., Sato, N., Voors, A. A., Stasch, J. P., & Butler, J. (2013). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Failure Reviews, 18(2), 123–134. https://doi.org/10.1007/S10741-012-9323-1/METRICS DOI: https://doi.org/10.1007/s10741-012-9323-1
González-Juanatey, J. R., Anguita-Sánchez, M., Bayes-Genís, A., Comín-Colet, J., García-Quintana, A., Recio-Mayoral, A., Zamorano-Gómez, J. L., Cepeda-Rodrigo, J. M., & Manzano, L. (2022). Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica. Revista Clínica Española, 222(6), 359–369. https://doi.org/10.1016/j.rce.2021.12.005 DOI: https://doi.org/10.1016/j.rce.2021.12.005
Gustavo, I.-C., Juan Ramón, H.-G., Roció Milagro, L.-L., José Manuel, O.-A., René, V.-M., & Valenzuela Alibe Natanai, P. (2021). Insuficiencia cardiaca crónica con fracción de eyección reducida: abordaje teórico, clínico y terapéutico. Chronic heart failure with reduced ejection fraction: theoretical, clini-cal and therapeutic approach. REVMEDUAS 333 Rev Med UAS, 11(4), 7191–9895. https://doi.org/10.28960/revmeduas.2007-8013.v11.n4.008 DOI: https://doi.org/10.28960/revmeduas.2007-8013.v11.n4.008
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012 DOI: https://doi.org/10.1016/j.jacc.2021.12.012
Hussain, A., Misra, A., & Bozkurt, B. (2022). Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 8. https://doi.org/10.15420/CFR.2021.13 DOI: https://doi.org/10.15420/cfr.2021.13
Pieske, B., Patel, M. J., Westerhout, C. M., Anstrom, K. J., Butler, J., Ezekowitz, J., Hernandez, A. F., Koglin, J., Lam, C. S. P., Ponikowski, P., Roessig, L., Voors, A. A., O’Connor, C. M., & Armstrong, P. W. (2019). Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. European Journal of Heart Failure, 21(12), 1596–1604. https://doi.org/10.1002/EJHF.1664 DOI: https://doi.org/10.1002/ejhf.1664
Ponikowski, P., Alemayehu, W., Oto, A., Bahit, M. C., Noori, E., Patel, M. J., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B., Roessig, L., Voors, A. A., Westerhout, C., & Armstrong, P. W. (2021). Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. European Journal of Heart Failure, 23(8), 1300–1312. https://doi.org/10.1002/EJHF.2285 DOI: https://doi.org/10.1002/ejhf.2285
Rodríguez-Artalejo, F., Banegas Banegas, J. R., & Guallar-Castillón, P. (2004). Epidemiología de la insuficiencia cardíaca. Revista Española de Cardiología, 57(2), 163–170. https://doi.org/10.1157/13057268 DOI: https://doi.org/10.1016/S0300-8932(04)77080-3
Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015). Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality. New England Journal of Medicine, 372(14), 1333–1341. https://doi.org/10.1056/nejmoa1406656 DOI: https://doi.org/10.1056/NEJMoa1406656
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Melinton Miguel López Ruano
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los autores/as que publiquen en esta revista aceptan las siguientes condiciones:
- Los autores/as conservan los derechos de autor y ceden a la revista el derecho de la primera publicación, con el trabajo registrado con la licencia de atribución de Creative Commons 4.0, que permite a terceros utilizar lo publicado siempre que mencionen la autoría del trabajo y a la primera publicación en esta revista.
- Los autores/as pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
- Se permite y recomienda a los autores/as a compartir su trabajo en línea (por ejemplo: en repositorios institucionales o páginas web personales) antes y durante el proceso de envío del manuscrito, ya que puede conducir a intercambios productivos, a una mayor y más rápida citación del trabajo publicado (vea The Effect of Open Access).
- Se permite a los autores la publicación de erratas y por otra parte se responsabilizan de la retractación de artículos.